Meet AJ and Bonnie
"AJ was diagnosed with severe hemophilia A at 2 days old, but the signs were there at birth. We didn't have a clear path forward. The hospital staff just told us to go home and be careful. We had to visit the hospital for a few nonspontaneous bleeds after that. Our specialist put him on prophy treatment because we agreed it would provide the best protection for AJ, and we've stayed on prophy since. He had a port installed when he was 16 months old so we could infuse at home.
The older he gets, the more active he's become. We've found our stride in managing AJ's hemophilia, but lately, our biggest challenge has been keeping a regular infusion schedule. AJ is very active at hemophilia camp and in 4H, plus he's a teenager, and sometimes it's hard to keep him focused and on schedule with infusions. Plus, AJ's veins showed some collapse because of more frequent access, and that made us even more concerned about his infusion routine. That's why ALTUVIIIO prophylaxis was such an exciting prospect for us.
ALTUVIIIO is the only once-weekly prophylaxis Factor VIlI therapy, and in our situation, that treatment schedule was appealing. ALTUVIIIO was also shown to have higher-for-longer factor levels at over 40% for most of the week. ALTUVIIIO's higher factor levels were associated with a low risk of bleeds and the once-weekly dosing would allow him to do things like take a week-long vacation without worrying about prophylaxis infusions."
Bonnie and AJ are promotional speakers compensated by Sanofi.
"AJ was diagnosed with severe hemophilia A at 2 days old, but the signs were there at birth. We didn't have a clear path forward. The hospital staff just told us to go home and be careful. We had to visit the hospital for a few nonspontaneous bleeds after that. Our specialist put him on prophy treatment because we agreed it would provide the best protection for AJ, and we've stayed on prophy since. He had a port installed when he was 16 months old so we could infuse at home.
The older he gets, the more active he's become. We've found our stride in managing AJ's hemophilia, but lately, our biggest challenge has been keeping a regular infusion schedule. AJ is very active at hemophilia camp and in 4H, plus he's a teenager, and sometimes it's hard to keep him focused and on schedule with infusions. Plus, AJ's veins showed some collapse because of more frequent access, and that made us even more concerned about his infusion routine. That's why ALTUVIIIO prophylaxis was such an exciting prospect for us.
ALTUVIIIO is the only once-weekly prophylaxis Factor VIlI therapy, and in our situation, that treatment schedule was appealing. ALTUVIIIO was also shown to have higher-for-longer factor levels at over 40% for most of the week. ALTUVIIIO's higher factor levels were associated with a low risk of bleeds and the once-weekly dosing would allow him to do things like take a week-long vacation without worrying about prophylaxis infusions."
Bonnie and AJ are promotional speakers compensated by Sanofi.
Hear from more patients
